Hypoxic trophoblast-derived sFlt-1 may contribute to endothelial dysfunction: Implication for the mechanism of trophoblast-endothelial dysfunction in preeclampsia

Cell Biology International

Volumn 35, Issue 1, 2011, Pages 61-66

  Zhou, Qiong ^a   Qiao, Fu Yuan ^a   Zhao, Chang ^b   Liu, Hai Yi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan No 1 Hospital   (China)

Author keywords

Endothelium dysfunction; Preeclampsia; sFlt 1; Trophoblast cell; VEGF

Indexed keywords

MESSENGER RNA; NITRIC OXIDE; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CAUSAL ATTRIBUTION; CELL CONTACT; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PATHOGENESIS; PREECLAMPSIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; TROPHOBLAST; UMBILICAL VEIN;

CELL COMMUNICATION; CELL HYPOXIA; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; NITRIC OXIDE; PRE-ECLAMPSIA; PREGNANCY; RNA, SMALL INTERFERING; TROPHOBLASTS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

TOBACCO ETCH VIRUS;

EID: 78649663232     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20100020     Document Type: Article

References (20)

1. Feng HC, Choy MY, Deng W, Wong HL, Lau WM, Cheung AN et al. Establishment and characterization of a human first-trimester extravillous trophoblast cell line (TEV-1). J Soc Gynecol Investig 2005;12:e21-32.
2. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003;63:3919-22.
3. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008;294:H541-50.
4. LaMarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 2008;51:982-8.
5. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007;50:686-92.
6. Lockwood CJ, Toti P, Arcuri F, Norwitz E, Funai EF, Huang ST et al. Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. Am J Pathol 2007;170:1398-405.
7. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007;71:977-84.
8. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1 (sFltl) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
9. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008;75:1-8.
10. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004;145:4838-45.
11. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006;291 :R1085-93.
12. Polliotti BM, Fry AG, Sailer DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-74.
13. Poston L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep 2006;58 Suppl:69-74.
14. Rabbani ML, Rogers PA. Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. Reproduction 2001;122:85-90.
15. Smith GC, Wear H. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 2009;21:111-6.
16. Tao J, Tu YT, Li JW, Feng AP, Huang CZ, Wu Y et al. Endogenous production of nitric oxide contributes to proliferation effect of vascular endothelial growth factor-induced malignant melanoma cell. Clin Exp Dermatol 2006;31:94-9.
17. Tripathi R, Rath G, Jain A, Salhan S. Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. Ann Anat 2008;190:477-89.
18. Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 2006;27:70-8.
19. van Nieuw Amerongen GP, Vermeer MA, Negre-Aminou P, Lankelma J, Emeis JJ, van Hinsbergh VW. Simvastatin improves disturbed endothelial barrier function. Circulation 2000;102:2803-9.
20. Zhu H, Bunn HF. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 1999;115:239-47.